Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904

Autor: Coleman, Robert L., Moon, James, Sood, Anil K., Hu, Wei, Delmore, James E., Bonebrake, Albert J., Anderson, Garnet L., Chambers, Setsuko K., Markman, Maurie
Zdroj: In European Journal of Cancer June 2014 50(9):1638-1648
Databáze: ScienceDirect
Externí odkaz: